Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 72% of modeled bridge. Strengths: Occupancy Rate. Risks: Bed Count, Commercial Payer %. Risk-adjusted uplift: $38.9M (vs $53.9M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $20.5M | $20.5M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $19.7M | $564K | $20.3M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $3.1M | $9.3M | $12.5M | $39.3M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $656K | $656K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 25.2% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $5.1M | $10.3M | $15.4M | $20.5M | $20.5M | $20.5M | $20.5M |
| Denial Rate Reduction | $0 | $5.1M | $10.2M | $15.2M | $20.3M | $20.3M | $20.3M | $20.3M |
| A/R Days Reduction | $0 | $4.2M | $8.3M | $12.5M | $12.5M | $12.5M | $12.5M | $12.5M |
| Clean Claim Rate | $0 | $328K | $656K | $656K | $656K | $656K | $656K | $656K |
| Cumulative | $0 | $14.7M | $29.4M | $43.7M | $53.9M | $53.9M | $53.9M | $53.9M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $53.9M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 71% / 14.5x | 75% / 16.5x | 79% / 18.5x | 81% / 19.4x | 83% / 20.4x |
| 9.0x | 66% / 12.5x | 70% / 14.3x | 74% / 16.1x | 76% / 16.9x | 78% / 17.8x |
| 10.0x | 61% / 11.0x | 66% / 12.5x | 70% / 14.1x | 72% / 14.9x | 73% / 15.7x |
| 11.0x | 57% / 9.7x | 62% / 11.1x | 66% / 12.5x | 68% / 13.3x | 69% / 14.0x |
| 12.0x | 54% / 8.6x | 58% / 9.9x | 62% / 11.2x | 64% / 11.9x | 66% / 12.5x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 43% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 3.7x, adding 4.7 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $42.5M | — | $42.5M | 4.1% |
| Year 1 | $43.8M | +$36.0M | $79.7M | 7.8% |
| Year 2 | $45.1M | +$53.9M | $99.0M | 9.7% |
| Year 3 | $46.4M | +$53.9M | $100.4M | 9.8% |
| Year 4 | $47.8M | +$53.9M | $101.8M | 9.9% |
| Year 5 | $49.3M | +$53.9M | $103.2M | 10.1% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $10.3M | $15.4M | $20.5M | $24.6M |
| Denial Rate Reductio | $10.2M | $15.2M | $20.3M | $24.4M |
| A/R Days Reduction | $6.2M | $9.4M | $12.5M | $15.0M |
| Clean Claim Rate | $328K | $492K | $656K | $787K |
| Total | $27.0M | $40.5M | $53.9M | $64.7M |
Peer Context — Where This Hospital Sits
Key metrics vs 54 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 4.1% | -15.4% | 3.5% | 12.6% | P50 |
| Net-to-Gross | 26.8% | 12.9% | 18.2% | 25.2% | P78 |
| Occupancy | 96.9% | 66.0% | 73.9% | 80.3% | P96 |
| Rev/Bed | $1.6M | $1.2M | $1.4M | $1.7M | P63 |
| Exp/Bed | $1.5M | $1.0M | $1.5M | $1.9M | P52 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.